PROM2 and lung cancer: Mechanically, cisplatin induces dormant and reactivated lung cancer cells, and CTCF governs the entry of cancer cells into dormant states and control the re-entry of dormant cancer cells into the cell cycle.29 Thus, we suspected that CTCF up-regulates PROM2 expression and governs the shift of cellular dormancy and reactivation under cisplatin stimulation, subsequently promotes cell proliferation and inhibits apoptosis, thereby reducing the cisplatin sensitivity.